Business Description

Vectus Biosystems Ltd
Compare
Compare
Traded in other countries / regions
VBS.Australia Description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.21 | |||||
Equity-to-Asset | -0.9 | |||||
Debt-to-Equity | -1.7 | |||||
Debt-to-EBITDA | -1.83 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 1 | |||||
3-Year EPS without NRI Growth Rate | -20.8 | |||||
3-Year FCF Growth Rate | -43.9 | |||||
3-Year Book Growth Rate | 15.4 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 42.29 | |||||
9-Day RSI | 40.09 | |||||
14-Day RSI | 39.49 | |||||
6-1 Month Momentum % | -3.55 | |||||
12-1 Month Momentum % | -41.58 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.5 | |||||
Quick Ratio | 0.5 | |||||
Cash Ratio | 0.17 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.8 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -86.93 | |||||
ROIC % | -81.83 | |||||
ROC (Joel Greenblatt) % | -710.91 | |||||
ROCE % | -712.74 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -12.81 | |||||
EV-to-EBITDA | -12.88 | |||||
EV-to-FCF | -9.88 | |||||
Earnings Yield (Greenblatt) % | -7.81 |